Vitamin C and Cancer Treatment: A Second Look

Recent research has reignited scientific interest in vitamin C as a potential adjunct in cancer treatment, with new findings suggesting that high-dose intravenous vitamin C may enhance the effectiveness of certain therapies while reducing side effects in some patients.

A review published in April 2024 in the journal Antioxidants & Redox Signaling analyzed preclinical and clinical data on vitamin C’s role in oncology, concluding that while oral vitamin C has limited impact due to poor bioavailability, intravenous administration can achieve plasma concentrations sufficient to exert pro-oxidant effects in tumor cells.

These elevated levels may generate hydrogen peroxide in the extracellular space, which cancer cells are less equipped to neutralize compared to healthy cells, potentially leading to selective tumor cell damage.

The review highlights several phase I and II clinical trials where intravenous vitamin C was combined with standard treatments such as chemotherapy and radiation. In one trial involving patients with pancreatic cancer, those receiving intravenous vitamin C alongside gemcitabine showed improved overall survival and reduced fatigue compared to chemotherapy alone.

Another study in patients with non-small cell lung cancer reported that adding intravenous vitamin C to carboplatin and paclitaxel resulted in better quality of life scores and decreased treatment-related toxicity without compromising tumor response rates.

Despite these promising signals, researchers emphasize that vitamin C is not a standalone cancer cure. Its potential role remains investigational and current evidence does not support replacing conventional therapies with vitamin C alone.

Dr. Jeanne Drisko, director of the University of Kansas Integrative Medicine program and a co-author of the review, noted that mechanistic studies support further investigation but cautioned against overinterpreting early results.

We are seeing signals that intravenous vitamin C may help make standard treatments more tolerable and possibly more effective in certain cancers, but we need larger, randomized phase III trials to confirm these findings.

Dr. Jeanne Drisko, University of Kansas Medical Center

The National Institutes of Health (NIH) has acknowledged the biological plausibility of high-dose vitamin C in cancer contexts but maintains that clinical evidence remains insufficient for routine recommendation. The NIH’s Office of Dietary Supplements states that while intravenous vitamin C appears safe when administered properly, its efficacy outside of clinical trials has not been established.

Ongoing trials are examining vitamin C’s impact in combination with immunotherapy, particularly in melanoma and ovarian cancer. A multi-institutional study led by the Mayo Clinic is currently assessing whether intravenous vitamin C can improve progression-free survival when added to checkpoint inhibitors in patients with advanced non-small cell lung cancer.

Experts warn against self-administering high-dose vitamin C without medical supervision. Intravenous delivery requires clinical oversight to monitor fluid balance, kidney function, and potential interactions with other medications. High oral doses can cause gastrointestinal distress and are unlikely to reach therapeutic blood levels.

As research continues, the focus remains on identifying which cancer types and patient populations may benefit most from vitamin C as a complementary approach. Until definitive trial results emerge, vitamin C’s role in cancer care remains an area of active scientific inquiry rather than established clinical practice.